for Health Care Providers
Supplemental Table 1: Treatment Monitoring Guidelines for Patients on Peginterferon-Ribavirin plus or minus Protease Inhibitor (Boceprevir or Telaprevir)
*Intervals may need to be increased based on patient tolerance and response to treatment in patients with significant declines in blood counts, renal insufficiency, diabetes, cirrhosis or other indications.
**Recommended for all patients at baseline and periodically during antiviral treatment in patients with diabetes, hypertension or as needed for visual complaints.
|Necessary||0||2||4||8||12||24||Every 4-weeks Thereafter||End-of-Treatment||24 weeks Post-treatment|
|HCV RNA||√||√||√||√||√||Follow Algorithm for additional timepoints||√||√|
|CBC with differential||√||√||√||√||√||√||√*||√|
|Liver function tests||√||√||√||√||√||√||√*||√|
|Psychiatric/Substance Use Screening||√||√||√||√||√||√||√*|
|Uric acid (if on telaprevir)||√||√||√||√||√||√||*||√||√|
|Urine Toxicology Screen||√|